Similar to Q1’s deal dollars and volume, device companies raised $1.06 billion through 45 transactions; Bayer HealthCare’s $1 billion purchase of Conceptus was the only device M&A in Q2 to exceed the billion-dollar mark. Diagnostics players raised a total of $2.9 billion during the second quarter, a huge increase over Q1 due to Thermo Fisher Scientific’s $2.46 billion follow-on offering to support its $15.2 billion April acquisition of Life Technology, another Q2 outlier in the M&A category.

The year might have started off slow for start-up fundraising ($398.7 million in Q1), but during the second quarter of 2013 life science companies rallied and earned a whopping $907.2 million. There were several reverse licensing arrangements as well as alliances involving large molecule-focused start-ups.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.

Brief profiles of these recently formed companies: advanceCOR, Aegis Women’s Health Technologies, dBMEDx, Exscien, OsteoVantage, and Trice Orthopedics.